Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.
NCT ID: NCT05378997
Last Updated: 2024-03-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
35 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-04-07
Study Completion Date
2024-03-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a three-part, Phase I, first-in-human study designed to evaluate the safety, tolerability, and potential systemic exposure of multiple topical doses of TCP-25. Part I includes healthy volunteers with acute epidermal wounds formed by the suction blister technique. Part II includes patients with non-healing leg ulcers and Part III patients with dystrophic epidermolysis bullosa (DEB).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
NCT06594393
Epidermolysis Bullosa (EB)
NOT_YET_RECRUITING
PHASE2
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
NCT00351767
Foot Ulcer, Diabetic
COMPLETED
PHASE2
The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa
NCT00380640
Epidermolysis Bullosa
COMPLETED
PHASE2
A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
NCT00069446
Foot Ulcer
COMPLETED
PHASE1
A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa
NCT01528306
Dystrophic Epidermolysis Bullosa
WITHDRAWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Blister
Wound of Skin
Epidermolysis Bullosa
Varicose Ulcer of Lower Limb
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Part I: Multiple topical doses of TCP-25 will be administered in 3 sequential dose groups, each of 8 subjects. Within each cohort, the subjects will receive TCP-25 on one wound on each thigh and placebo on one wound on each thigh in a randomized fashion as topical treatment. In Part II: Multiple topical doses of TCP-25 will be administered to 6 patients with non-healing leg ulcers. In Part III: Up to 4 dose levels of TCP-25 will be administered in up to 5 patients with DEB by topical application of TCP-25 gel of two concentrations.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose group 1
0.15 mL of TCP-25 gel (0.86 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
Group Type
EXPERIMENTAL
TCP-25 gel 0.86 mg/ml or placebo gel
Intervention Type
DRUG
TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Dose group 2
0.15 mL of TCP-25 gel (2.9 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
Group Type
EXPERIMENTAL
TCP-25 gel 2.9 mg/ml or placebo gel
Intervention Type
DRUG
TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Dose group 3
0.15 mL of TCP-25 gel (8.6 mg/mL) or 0.15 mL placebo gel per wound applied as topical treatment on days 1, 2, 3, 5, and 8
Group Type
EXPERIMENTAL
TCP-25 gel 8.6 mg/ml or placebo gel
Intervention Type
DRUG
TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TCP-25 gel 0.86 mg/ml or placebo gel
TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Intervention Type
DRUG
TCP-25 gel 2.9 mg/ml or placebo gel
TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Intervention Type
DRUG
TCP-25 gel 8.6 mg/ml or placebo gel
TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing and able to give written informed consent for participation in the study.
2. Healthy male or female subject 18-60 years (inclusive) of age at the time of signing the informed consent.
3. Body Mass Index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2.
4. Healthy and intact skin where the blister suction wounds will be induced.
5. Women of childbearing potential (WOCBP) must have a documented negative serum pregnancy test done at the screening visit, within 4 weeks prior to suction blister formation and the start of study treatment.
WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the subject) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined \[oestrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\] or intrauterine hormone-releasing system \[IUS\]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female subjects must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IE/L is confirmatory).
Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above).
6. Clinically relevant medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
1. Willing and able to give written informed consent for participation in the study.
2. Male patient, or female patient of non-childbearing potential, ≥40 years of age at the time of signing the informed consent.
3. Male subjects must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IU/L is confirmatory).
4. Clinically relevant medical history, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
5. Patients diagnosed with venous insufficiency by relevant physiological tests including doppler or venous plethysmography or diagnosed by relevant clinical evaluations.
6. Systolic index \> 0.6 (Data from medical records from the last 2 years, or the assessment should be repeated at the screening visit).
7. Ulcer duration \> 6 weeks
8. Total target ulcer area applicable for treatment: ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit). (The target ulcer area may not consist of \>2 separate ulcers.)
9. Ability to tolerate compression bandaging.
10. Willing to attend study site visits.
1. Willing and able to give written informed consent for participation in the study. For 15 to 17-year-olds: A separate consent is required from both (if applicable) the patient's parents/legal guardians.
2. Male or female patient with documented diagnosis of inherited DEB, ≥15 years of age at the time of signing the informed consent.
3. Male patients must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy.
WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the patient) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined \[oestrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\] or intrauterine hormone-releasing system \[IUS\]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female patients must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IU/L is confirmatory).
4. Clinically relevant medical history at the time of screening, as judged by the Investigator.
5. Presence of two target wound areas of 50 cm2. The primary wound area should not be located at anatomical sites with high likelihood of accidental trauma (e.g., knee, elbow). The secondary wound area could be located at anatomical sites with high likelihood of accidental trauma or be within the higher age span. Both wound areas should meet all the following characteristics:
1. Including open wound with a surface area of ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit).
2. At Visit 2 (first IMP treatment), each target wound should not present a surface reduction ≥ 30 % from the Screening visit.
3. Wound aged ≥ 3 weeks to \< 9 months at the Screening visit.
6. Presence of a reference wound area of 50 cm2 to be treated with standard of care only and to be included in the exploratory assessment. The wound area should match the primary wound area for following characteristics:
1. Including open wound with a surface area of ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit).
2. At Visit 2 (first IMP treatment), the wound should not present a surface reduction ≥ 30 % from the Screening visit.
3. Wound aged ≥ 3 weeks to \< 9 months at the Screening visit.
4. Not located at anatomical sites with high likelihood of accidental trauma (e.g., knee, elbow).
7. Willing to attend study site visits.
2. Healthy male or female subject 18-60 years (inclusive) of age at the time of signing the informed consent.
3. Body Mass Index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2.
4. Healthy and intact skin where the blister suction wounds will be induced.
5. Women of childbearing potential (WOCBP) must have a documented negative serum pregnancy test done at the screening visit, within 4 weeks prior to suction blister formation and the start of study treatment.
WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the subject) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined \[oestrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\] or intrauterine hormone-releasing system \[IUS\]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female subjects must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IE/L is confirmatory).
Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above).
6. Clinically relevant medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
1. Willing and able to give written informed consent for participation in the study.
2. Male patient, or female patient of non-childbearing potential, ≥40 years of age at the time of signing the informed consent.
3. Male subjects must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IU/L is confirmatory).
4. Clinically relevant medical history, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
5. Patients diagnosed with venous insufficiency by relevant physiological tests including doppler or venous plethysmography or diagnosed by relevant clinical evaluations.
6. Systolic index \> 0.6 (Data from medical records from the last 2 years, or the assessment should be repeated at the screening visit).
7. Ulcer duration \> 6 weeks
8. Total target ulcer area applicable for treatment: ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit). (The target ulcer area may not consist of \>2 separate ulcers.)
9. Ability to tolerate compression bandaging.
10. Willing to attend study site visits.
1. Willing and able to give written informed consent for participation in the study. For 15 to 17-year-olds: A separate consent is required from both (if applicable) the patient's parents/legal guardians.
2. Male or female patient with documented diagnosis of inherited DEB, ≥15 years of age at the time of signing the informed consent.
3. Male patients must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of last dosing until 3 months after the last dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy.
WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the patient) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined \[oestrogen and progestogen containing\] hormonal contraception associated with inhibition of ovulation \[oral, intravaginal, transdermal\], progestogen-only hormonal contraception associated with inhibition of ovulation \[oral, injectable, implantable\], intrauterine device \[IUD\] or intrauterine hormone-releasing system \[IUS\]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female patients must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] 25-140 IU/L is confirmatory).
4. Clinically relevant medical history at the time of screening, as judged by the Investigator.
5. Presence of two target wound areas of 50 cm2. The primary wound area should not be located at anatomical sites with high likelihood of accidental trauma (e.g., knee, elbow). The secondary wound area could be located at anatomical sites with high likelihood of accidental trauma or be within the higher age span. Both wound areas should meet all the following characteristics:
1. Including open wound with a surface area of ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit).
2. At Visit 2 (first IMP treatment), each target wound should not present a surface reduction ≥ 30 % from the Screening visit.
3. Wound aged ≥ 3 weeks to \< 9 months at the Screening visit.
6. Presence of a reference wound area of 50 cm2 to be treated with standard of care only and to be included in the exploratory assessment. The wound area should match the primary wound area for following characteristics:
1. Including open wound with a surface area of ≤ 30 cm2 (as measured with the Silhouette imaging equipment at the screening visit).
2. At Visit 2 (first IMP treatment), the wound should not present a surface reduction ≥ 30 % from the Screening visit.
3. Wound aged ≥ 3 weeks to \< 9 months at the Screening visit.
4. Not located at anatomical sites with high likelihood of accidental trauma (e.g., knee, elbow).
7. Willing to attend study site visits.
Exclusion Criteria
1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
2. Disease that may interfere with wound healing, e.g., diabetes type I/II, arterial-, renal-, liver, or cardiac insufficiency, chronic obstructive lung disease, cancer, autoimmune disease, edema at the study site, severe obesity, or previous known wound healing problems, as judged by the investigator.
3. Active skin disease, e.g., dermatitis, psoriasis and wounds, and/or tattoos in the areas where suction blister wounds will be induced, as judged by the investigator.
4. Any planned major surgery within the duration of the study.
5. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
* Systolic blood pressure \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>100 mmHg, or
* Pulse \<40 or \>90 beats per minute (bpm)
6. Any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
7. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
8. Female subjects who are pregnant or lactating or planning a pregnancy.
9. Systemic immunosuppressive treatment.
10. Subjects who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study: - systemic corticosteroids or immunosuppressant agents; or - antibiotics via any route
11. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants per Investigator's judgement) or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
13. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
14. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
15. Presence or history of drug abuse, as judged by the Investigator
16. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
17. Involvement in the planning and/or conduct of the study.
18. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Part II:
1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
2. Disease that may interfere with wound healing, e.g., diabetes type I/II, arterial-, renal-, liver, or cardiac insufficiency, chronic obstructive lung disease, cancer, autoimmune disease, edema at the study site, severe obesity, or previous known wound healing problems, as judged by the Investigator.
3. Active skin disease, e.g., dermatitis, psoriasis and wounds, and/or tattoos in the areas where suction blister wounds will be induced, as judged by the Investigator.
4. Any planned major surgery within the duration of the study.
5. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
* Systolic blood pressure \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>100 mmHg, or
* Pulse \<40 or \>90 beats per minute (bpm)
6. Any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
7. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
8. Female subjects who are pregnant or lactating or planning a pregnancy.
9. Systemic immunosuppressive treatment.
10. Subjects who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study:
* systemic corticosteroids or immunosuppressant agents; or
* antibiotics via any route
11. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants per Investigator's judgement) or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
13. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
14. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
15. Presence or history of drug abuse, as judged by the Investigator.
16. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
17. Involvement in the planning and/or conduct of the study.
18. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
1. Presence or documented illness, which in the Investigator's opinion may negatively affect wound healing or interfere with the study conduct.
2. Target wound present for more than 5 years.
3. Clinical signs of infection in or around the wound in need of antibiotic treatment.
4. Albumin \<25 g/L or capillary Hb \<90 g/L, or HbA1c \> 70 mmol/mol at the time of the screening visit.
5. Any planned major surgery within the duration of the study.
6. Patients who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study:
* systemic corticosteroids above 5 mg prednisolone or equivalent, or
* immunosuppressant agents; or
* antibiotics via any route.
7. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants affecting APTT and/or PK/INR per Investigator's judgement) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
9. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
10. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
11. Involvement in the planning and/or conduct of the study.
12. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.
Part III:
1. Any subtype of EB other than DEB.
2. EB index wounds that have infection in need of systemic antibiotic treatment.
3. Presence of or documented illness, which in the Investigator's opinion may negatively affect wound healing or interfere with the study conduct.
4. Subject has evidence of a systemic infection or has used systemic antibiotics for EB-related infections within 7 days before the screening visit (Visit 1).
5. Administration of systemic corticosteroids within 30 days (\> 10 mg daily of prednisolone or corresponding) or of topical corticosteroids on target wound areas (primary, secondary and reference wound areas) within 14 days before the screening visit (Visit 1). Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted.
6. Subject has undergone stem cell transplant or gene therapy for the treatment of EB with an effect on target wounds.
7. History of malignancy, including basal cell carcinomas or squamous cell carcinomas in the wound areas that will be included in the study.
8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
9. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
10. Involvement in the planning and/or conduct of the study.
11. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.
2. Disease that may interfere with wound healing, e.g., diabetes type I/II, arterial-, renal-, liver, or cardiac insufficiency, chronic obstructive lung disease, cancer, autoimmune disease, edema at the study site, severe obesity, or previous known wound healing problems, as judged by the investigator.
3. Active skin disease, e.g., dermatitis, psoriasis and wounds, and/or tattoos in the areas where suction blister wounds will be induced, as judged by the investigator.
4. Any planned major surgery within the duration of the study.
5. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
* Systolic blood pressure \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>100 mmHg, or
* Pulse \<40 or \>90 beats per minute (bpm)
6. Any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
7. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
8. Female subjects who are pregnant or lactating or planning a pregnancy.
9. Systemic immunosuppressive treatment.
10. Subjects who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study: - systemic corticosteroids or immunosuppressant agents; or - antibiotics via any route
11. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants per Investigator's judgement) or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
13. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
14. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
15. Presence or history of drug abuse, as judged by the Investigator
16. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
17. Involvement in the planning and/or conduct of the study.
18. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Part II:
1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
2. Disease that may interfere with wound healing, e.g., diabetes type I/II, arterial-, renal-, liver, or cardiac insufficiency, chronic obstructive lung disease, cancer, autoimmune disease, edema at the study site, severe obesity, or previous known wound healing problems, as judged by the Investigator.
3. Active skin disease, e.g., dermatitis, psoriasis and wounds, and/or tattoos in the areas where suction blister wounds will be induced, as judged by the Investigator.
4. Any planned major surgery within the duration of the study.
5. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges:
* Systolic blood pressure \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>100 mmHg, or
* Pulse \<40 or \>90 beats per minute (bpm)
6. Any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
7. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
8. Female subjects who are pregnant or lactating or planning a pregnancy.
9. Systemic immunosuppressive treatment.
10. Subjects who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study:
* systemic corticosteroids or immunosuppressant agents; or
* antibiotics via any route
11. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants per Investigator's judgement) or non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
13. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
14. History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
15. Presence or history of drug abuse, as judged by the Investigator.
16. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
17. Involvement in the planning and/or conduct of the study.
18. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
1. Presence or documented illness, which in the Investigator's opinion may negatively affect wound healing or interfere with the study conduct.
2. Target wound present for more than 5 years.
3. Clinical signs of infection in or around the wound in need of antibiotic treatment.
4. Albumin \<25 g/L or capillary Hb \<90 g/L, or HbA1c \> 70 mmol/mol at the time of the screening visit.
5. Any planned major surgery within the duration of the study.
6. Patients who are currently receiving or have received the following treatments within 2 weeks prior to screening are excluded from the study:
* systemic corticosteroids above 5 mg prednisolone or equivalent, or
* immunosuppressant agents; or
* antibiotics via any route.
7. Regular use of anticoagulants (i.e., heparin, warfarin, coumarins, other anticoagulants affecting APTT and/or PK/INR per Investigator's judgement) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
9. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
10. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
11. Involvement in the planning and/or conduct of the study.
12. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.
Part III:
1. Any subtype of EB other than DEB.
2. EB index wounds that have infection in need of systemic antibiotic treatment.
3. Presence of or documented illness, which in the Investigator's opinion may negatively affect wound healing or interfere with the study conduct.
4. Subject has evidence of a systemic infection or has used systemic antibiotics for EB-related infections within 7 days before the screening visit (Visit 1).
5. Administration of systemic corticosteroids within 30 days (\> 10 mg daily of prednisolone or corresponding) or of topical corticosteroids on target wound areas (primary, secondary and reference wound areas) within 14 days before the screening visit (Visit 1). Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted.
6. Subject has undergone stem cell transplant or gene therapy for the treatment of EB with an effect on target wounds.
7. History of malignancy, including basal cell carcinomas or squamous cell carcinomas in the wound areas that will be included in the study.
8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to TCP-25 or to any excipients of the hydrogel.
9. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1.
10. Involvement in the planning and/or conduct of the study.
11. Investigator considers the patient unlikely to comply with study procedures, restrictions and requirements.
Minimum Eligible Age
15 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Skane
OTHER
Sponsor Role
collaborator
Xinnate AB
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skåne University Hospital in Lund, Clinical Trial Unit
Lund, , Sweden
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Sweden
References
Explore related publications, articles, or registry entries linked to this study.
Wallblom K, Forsberg F, Lundgren S, Fisher J, Cardoso J, Petruk G, Stromdahl AC, Saleh K, Puthia M, Schmidtchen A. Bactogram: Spatial Analysis of Bacterial Colonisation in Epidermal Wounds. Exp Dermatol. 2024 Dec;33(12):e70018. doi: 10.1111/exd.70018.
Reference Type
DERIVED
Lundgren S, Wallblom K, Fisher J, Erdmann S, Schmidtchen A, Saleh K. Study protocol for a phase 1, randomised, double-blind, placebo-controlled study to investigate the safety, tolerability and pharmacokinetics of ascending topical doses of TCP-25 applied to epidermal suction blister wounds in healthy male and female volunteers. BMJ Open. 2023 Feb 22;13(2):e064866. doi: 10.1136/bmjopen-2022-064866.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-004728-14
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
TCP-25-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of Topical Wound Oxygen (two2) Therapy
NCT00871312
TERMINATED
NA
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
NCT02014376
COMPLETED
PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863
NCT01831804
COMPLETED
PHASE1
Assessment of the Wound Healing Efficacy and Tolerance of a Medical Device on Wounds in Healthy Subjects.
NCT04687839
COMPLETED
NA
Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers
NCT00796744
COMPLETED
PHASE2
Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds
NCT05710094
COMPLETED
PHASE1
Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer
NCT00658957
TERMINATED
PHASE2
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
NCT02427802
COMPLETED
PHASE3
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
NCT04450693
COMPLETED
PHASE3
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
NCT02833389
COMPLETED
PHASE1
Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers
NCT02326337
COMPLETED
NA
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
NCT00316537
TERMINATED
PHASE1/PHASE2
Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers
NCT02447172
COMPLETED
PHASE3
Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds
NCT05169814
RECRUITING
EARLY_PHASE1
Dose Finding Study of HP802-247 in Venous Leg Ulcers
NCT00852995
COMPLETED
PHASE2
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
NCT01830348
TERMINATED
PHASE3
Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)
NCT04176120
COMPLETED
PHASE3
Topical Nitric Oxide Trial in Chronic Non-Healing Wounds
NCT00823095
TERMINATED
PHASE2
A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers
NCT02154087
TERMINATED
PHASE2
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
NCT05608187
TERMINATED
PHASE2
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
NCT03230175
COMPLETED
PHASE2
Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus
NCT02737722
COMPLETED
PHASE1/PHASE2
Tissue Repair Gel in Venous Leg Ulcers in AU/US
NCT06707103
RECRUITING
PHASE3
Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy
NCT02417779
COMPLETED
NA